[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577845":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":37,"responsibleParty":68,"collaborators":31,"id":71,"slug":31,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":31,"eligibilityCriteria":76,"healthyVolunteers":72,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":31,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":31,"overallStatus":39,"whyStopped":31,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment Group","EXPERIMENTAL","Patients with Gastroparesis",[13],"Drug: Growth Hormone",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Growth Hormone","Subjects will receive somapacitan-beco (Sogroya®) administered as a subcutaneous injection once weekly for 12 weeks.\n\nAll participants will receive a fixed dose of 1.5 mg weekly, regardless of sex.",[9],[21],"Sogroya (Somapacitan-beco injections)",[23],{"name":24,"affiliation":5,"role":25},"Tisha Lunsford","PRINCIPAL_INVESTIGATOR",[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Guillermo GI Program Coordinator, Research","CONTACT","480-301-4679",null,"barahona.guillermo@mayo.edu",{"name":34,"role":29,"phone":31,"phoneExt":35,"email":36},"Tisha Lunsford, MD","480-301-6990","lunsford.tisha@mayo.edu",[38,53],{"facility":5,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Phoenix","Arizona","85054","United States",{"type":45,"coordinates":46},"Point",[47,48],-112.07404,33.44838,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":30,"phoneExt":31,"email":31},"Guillermo Barahona Hernandez, Sr. Progam Coordiantor",{"facility":54,"status":39,"city":55,"state":41,"zip":56,"country":43,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Mayo Clinic in Arizona","Scottsdale","85259",{"type":45,"coordinates":58},[59,60],-111.89903,33.50921,{"lat":60,"lon":59},[63,65,66],{"name":64,"role":29,"phone":31,"phoneExt":31,"email":32},"Guillermo Barahona Hernandez, Program Coordinator, Research, 480-301-4679",{"name":34,"role":29,"phone":35,"phoneExt":31,"email":36},{"name":67,"role":25,"phone":31,"phoneExt":31,"email":31},"Tisha Najet Lunsford",{"type":25,"investigatorFullName":69,"investigatorTitle":70,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Tisha N. Lunsford","GI and Hepatology Consultant","100577845",false,"NCT06803589","Growth Hormone for the Treatment of Gastroparesis","Low-dose Growth Hormone for the Treatment of Gastroparesis","Inclusion Criteria:\n\n* Symptoms \\> 6 months that have not responded satisfactorily to standard treatment.\n* For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \\>21\n\nExclusion Criteria:\n\n* Known history of GH deficiency, hypothalamic or pituitary disease\n* Diabetes\n* Prior use of GH therapy\n* Age-adjusted low serum IGF1\n* Women on oral estrogen therapy6\n* Pregnancy or nursing\n* History of malignant solid tumors\n* Obesity (BMI \\> 30)History of coronary and thromboembolic diseases.\n* History of sarcoidosis\n* History of pituitary surgery\n* History of thyroid nodules.\n* Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study.\n* Failure to give informed consent.","ALL","18 Years","65 Years",{"count":81,"type":82},10,"ESTIMATED","INTERVENTIONAL",[85],"EARLY_PHASE1","The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.",[88],"Gastroparesis","2026-04-13",{"date":91,"type":92},"2026-04-16","ACTUAL",{"date":94,"type":92},"2024-10-22",{"date":96,"type":82},"2027-12",{"name":5,"class":6},2]